Daily Endocrinology Research Analysis
Analyzed 11 papers and selected 3 impactful papers.
Summary
Three impactful studies advance endocrine-metabolic medicine: a large cohort reveals a non-linear and CAD-dependent link between coagulation factor XI activity and mortality; a meta-analysis of 23 RCTs finds resveratrol does not meaningfully reduce weight but modestly lowers waist circumference; and a 15-year Japanese cohort shows renal sinus fat improves prediction of diabetic kidney disease beyond conventional adiposity metrics.
Research Themes
- Metabolic risk stratification and prognostic biomarkers
- Efficacy of nutraceuticals in obesity management
- Cardio-metabolic hemostasis and personalized therapeutics
Selected Articles
1. Non-linear association of coagulation factor XI with mortality.
In a 3,170-participant cohort with 14.5 years’ median follow-up, FXI activity showed a U-shaped association with all-cause mortality overall, but a linear risk increase among CAD patients. NT-proBNP significantly modified these relationships, underscoring the need to personalize FXI-targeted therapies.
Impact: This study provides nuanced, disease-context-dependent risk modeling for FXI and mortality, directly informing ongoing development of FXI inhibitors. The long follow-up and statistical rigor enhance translational relevance.
Clinical Implications: Baseline FXI and NT-proBNP should be considered when evaluating candidacy for FXI inhibition; patients with CAD and elevated FXI may be at heightened risk. Risk stratification should account for non-linear effects in non-CAD populations.
Key Findings
- FXI activity had a U-shaped association with mortality overall, with lowest risk at 115.6% activity (p=0.027).
- Among CAD patients, the relationship was linear: higher FXI activity correlated with increased mortality (p interaction < 0.0001).
- NT-proBNP significantly modified the FXI–mortality association, especially in CAD.
Methodological Strengths
- Large, well-characterized cohort (N=3,170) with long median follow-up (14.5 years).
- Advanced modeling with restricted cubic splines and interaction analyses; multivariable adjustment.
Limitations
- Observational design cannot prove causality and is susceptible to residual confounding.
- Single regional cohort (LURIC) may limit generalizability to other populations.
Future Directions: Prospective validation across diverse cohorts and randomized trials of FXI inhibitors stratified by baseline FXI and NT-proBNP; mechanistic studies on myocardial effects of FXI.
BACKGROUND: Coagulation factor XI (FXI) influences both thrombotic risk and myocardial function, making its relationship with mortality crucial for guiding therapies, especially in coronary artery disease (CAD). METHODS: We analyzed data from 3,170 participants who underwent coronary angiography; 67% were diagnosed with CAD. Participants were followed for a median of 14.5 years. Mortality risk was assessed using Cox proportional hazards models with restricted cubic splines and Wald statistics. Models were adjusted for age, sex, BMI, and further cardiovascular risk factors. Interactions between FXI activity, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and CAD were explored. FINDINGS: A U-shaped association between FXI activity and mortality was observed (p = 0.027), with the lowest risk at an FXI activity of 115.6%. Among patients without CAD, this U-shaped relationship persisted. In contrast, patients with CAD demonstrated a linear relationship, where higher FXI activity correlated with increased mortality (p interaction < 0.0001). NT-proBNP levels significantly modified these associations, particularly in patients with CAD. CONCLUSIONS: These findings emphasize the dual role of FXI activity in hemostasis, which could have profound implications for pharmacological interventions. The variable effects of FXI activity based on underlying cardiovascular conditions suggest that a personalized approach to treatment is necessary. Consequently, future studies on FXI inhibitors should carefully examine these modulating factors to optimize therapeutic strategies. FUNDING: The LURIC study was supported by the Ludwigshafen Heart Centre and academic collaborators, including the universities of Freiburg, Ulm, and Düsseldorf and the Centre Nationale de Genotypage in France, through internal institutional resources.
2. The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials.
Across 23 RCTs (n=1005), resveratrol did not significantly change weight, BMI, fat mass, adiponectin, or leptin, but reduced waist circumference by 1.93 cm. Subgroup signals suggest potential benefits with lower doses, longer duration, and in females.
Impact: This high-level synthesis clarifies inconsistent literature and provides actionable guidance by highlighting lack of overall efficacy on weight while identifying a modest effect on central adiposity.
Clinical Implications: Resveratrol should not be routinely recommended for weight loss in overweight/obese adults; modest waist circumference reduction may be considered for select patients. Counseling should emphasize limited benefits and the importance of lifestyle interventions.
Key Findings
- No significant effects on body weight, BMI, fat mass, body fat percentage, FFM, WHR, adiponectin, or leptin across 23 RCTs (n=1005).
- Waist circumference decreased significantly (WMD -1.93 cm; 95% CI -3.10 to -0.76; p=0.001).
- Subgroup analyses showed greater effects with doses <1000 mg/day, duration ≥12 weeks, and in females; FFM increased in participants <50 years.
Methodological Strengths
- PROSPERO-registered meta-analysis synthesizing 23 randomized controlled trials.
- Comprehensive database search with subgroup analyses by dose, duration, sex, and age.
Limitations
- Heterogeneity in dosing, duration, and populations likely limits inference and may dilute effects.
- Short-to-moderate intervention durations; long-term clinical outcomes remain unclear.
Future Directions: Standardized, adequately powered RCTs with longer duration focusing on central adiposity endpoints; individual patient data meta-analysis to validate subgroup effects.
BACKGROUND: The effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels remain inconclusive in individuals with overweight and obesity. METHOD: This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels. We searched electronic databases, including Scopus, Web of Science, and PubMed, up to September 2025, to identify eligible RCTs. RESULTS: A total of 23 RCTs, involving 1005 participants, met the inclusion criteria for the meta-analysis. Resveratrol supplementation did not significantly affect body weight (WMD: -1.42 kg; 95% CI: -3.19, 0.35; P = 0.117), body mass index (BMI) (WMD: -0.47 kg/m²; 95% CI: -0.96, 0.01; P = 0.055), fat mass (FM) (WMD: 0.47 kg; 95% CI: -1.75, 2.69; P = 0.679), body fat percentage (BFP) (WMD: -0.88%; 95% CI: -1.91, 0.15; P = 0.094), fat-free mass (FFM) (WMD: 1.42 kg; 95% CI: -1.04, 3.89; P = 0.257), waist-hip ratio (WHR) (WMD: -0.00; 95% CI: -0.01, 0.00; P = 0.436), adiponectin (WMD: 1.84 µg/mL; 95% CI: -2.25, 5.95; P = 0.378), or leptin (WMD: 1.87 ng/mL; 95% CI: -3.84, 7.60; P = 0.521). However, resveratrol supplementation significantly reduced waist circumference (WC) (WMD: -1.93 cm; 95% CI: -3.10, -0.76; P = 0.001). Subgroup analyses revealed significant reductions in body weight and BMI with doses <1000 mg/day, longer interventions (≥12 weeks), and in females. Additionally, FFM increased significantly among participants aged <50 years, and leptin levels were significantly elevated in both sexes. CONCLUSION: This meta-analysis showed that resveratrol supplementation did not significantly impact most anthropometric measures and serum leptin and adiponectin in individuals with overweight and obesity. However, it led to a significant reduction in waist circumference. The PROSPERO registration number: is CRD42024497932.
3. Peri-renal and sinus fat accumulation and diabetic kidney disease in type 2 diabetes: A Japanese cohort study.
In a 15-year Japanese cohort of 190 T2D adults free of DKD at baseline, CT-quantified renal fat indices—especially RSFVI—improved DKD risk prediction independently of traditional risk factors and general/abdominal adiposity metrics.
Impact: Introduces local renal fat as a clinically meaningful, imaging-based biomarker that augments DKD risk stratification beyond BMI and visceral fat.
Clinical Implications: Incorporating renal sinus fat quantification could refine early DKD risk stratification in T2D. Imaging protocols (e.g., low-dose CT or MRI surrogates) may help identify high-risk patients for intensified prevention.
Key Findings
- CT-derived PRFVI and RSFVI predicted incident DKD over 15 years in Japanese adults with T2D.
- RSFVI provided incremental predictive value independent of conventional DKD risk factors and general/abdominal adiposity indices.
- Risk stratification by adiposity tertiles highlighted the superiority of local renal fat metrics over BMI, VFA, and SFA.
Methodological Strengths
- Prospective 15-year follow-up with imaging-based quantification of renal and abdominal fat.
- Head-to-head comparison of multiple adiposity indices (BMI, VFA, SFA, PRFVI, RSFVI).
Limitations
- Modest sample size (n=190) and single-ethnicity cohort may limit generalizability.
- Use of CT entails radiation exposure and may limit routine adoption; abstract provides limited statistical detail.
Future Directions: Validation in larger, multiethnic cohorts and evaluation of MRI/ultrasound surrogates; interventional studies to test whether reducing renal fat lowers DKD risk.
AIMS: This 15-year cohort study assessed whether peri-renal fat volume index (PRFVI) and renal sinus fat volume index (RSFVI) predict diabetic kidney disease (DKD) better than general or abdominal obesity measures in Japanese adults with type 2 diabetes mellitus (T2D). METHODS: Researchers studied 190 DKD-free patients, measured their abdominal and renal fat via computed tomography, and categorized them into tertiles based on five adiposity indices: BMI, visceral fat area (VFA), subcutaneous fat area (SFA), PRFVI, and RSFVI. RESULTS: Participants averaged 58 years old; 52.6 % were male with a median diabetes duration of 5 years and a BMI of 25.4 kg/m CONCLUSIONS: The findings demonstrate that PRFVI, particularly RSFVI, provides incremental predictive value independent of conventional DKD risk variables, suggesting that local renal fat may be a target for early DKD detection and intervention in people with T2D.